8,824 TG Therapeutics, Inc. $TGTX Shares Acquired by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 15.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 67,221 shares of the biopharmaceutical company’s stock after purchasing an additional 8,824 shares during the period. Illinois Municipal Retirement Fund’s holdings in TG Therapeutics were worth $3,750,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Bank of America Corp DE boosted its stake in shares of TG Therapeutics by 71.7% in the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock worth $48,544,000 after buying an additional 610,195 shares during the last quarter. Deutsche Bank AG purchased a new stake in shares of TG Therapeutics during the second quarter valued at approximately $12,937,000. Jupiter Topco LLC purchased a new stake in shares of TG Therapeutics during the second quarter valued at approximately $5,319,000. PDT Partners LLC purchased a new stake in shares of TG Therapeutics during the second quarter valued at approximately $2,285,000. Finally, Man Group plc purchased a new stake in shares of TG Therapeutics during the second quarter valued at approximately $7,273,000. Institutional investors own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on TGTX shares. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research upgraded TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. Finally, B. Riley Financial boosted their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

TG Therapeutics Stock Performance

TGTX traded down $0.05 during midday trading on Friday, reaching $64.51. The company had a trading volume of 1,095,871 shares, compared to its average volume of 2,131,002. TG Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $68.03. The business has a 50-day moving average price of $56.69 and a two-hundred day moving average price of $45.33. The stock has a market cap of $9.75 billion, a PE ratio of 97.74, a P/E/G ratio of 5.08 and a beta of 1.89. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.72 and a current ratio of 4.50.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.01). TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The company had revenue of $259.94 million for the quarter, compared to analysts’ expectations of $245.47 million. During the same quarter in the previous year, the business earned $2.43 EPS. The company’s revenue for the quarter was up 60.8% on a year-over-year basis. On average, sell-side analysts expect that TG Therapeutics, Inc. will post 1.10 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.87% of the company’s stock.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.